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Abstract
It is generally believed that intervention on skin while on isotretinoin or within 6 to
12 months after treatment can lead to prolonged healing and abnormal scarring. The
objective of this systematic review is to evaluate the body of evidence on concomi-
tant use of isotretinoin and lasers for adverse events as a consequence of treatment.
A PRISMA-compliant systematic review (Systematic Review Registration Number:
CRD42017056492) of 12 electronic databases was conducted for the terms “laser”
and “isotretinoin” or associated brand names from inception until June 2020. Subse-
quent reference search of studies meeting predefined inclusion criteria were con-
ducted, and all articles were evaluated for bias and assigned levels of evidence to
facilitate data synthesis. The search strategy produced 29 studies. Of 871 patients
included in the studies of interest, 12 experienced transient adverse effects that
resolved spontaneously, and only two presented with keloid formation, both from
case reports. This systematic review suggests the risk associated with concomitant
isotretinoin and laser use is small to absent. Further studies are needed, but these
results suggest that current contraindications may be overly cautious.
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1 | INTRODUCTION
The American Academy of Dermatology guidelines recommends
delaying laser resurfacing 6 to 12 months after discontinuing isotreti-
noin, citing early case series describing delayed wound healing in
patients with concomitant use. Current recommendations rely heavily
on case reports published over three decades ago.
Acne is the most common skin condition in the United States,
affecting up to 50 million American annually.1 A subset of these
patients suffer from severe inflammatory acne, often presenting with
severe acne scars. There is evidence that early intervention results in
better outcomes.2,3 Therefore, it is important to consider the impact
on the patient when requesting delay of laser treatment due to guide-
lines developed from multiple-decade old case reports.
In 2017, two consensus statements considered several procedural
interventions in the setting of isotretinoin, challenging the common
practice of a latency period between systemic isotretinoin therapy
and other treatments. Since that time, several additional studies have
been published with no systematic review considering the adverse
consequences of concomitant laser and isotretinoin. Furthermore,
these studies did not report the efficacy, frequency, nor dosage of the
lasers; important metrics for understanding limitations of practical
laser use in this context. Our aim was to conduct a systematic review
that may inform evidence-based guidelines and shape clinic practice
for the benefit of the patient, focusing specifically on laser use.
2 | METHODS
The protocol was registered on International Prospective Register of
Systematic Reviews, and adheres to the principles of the PRISMA
guidelines4 (CRD42017056492).
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2.1 | Search strategy and study selection
We searched 12 databases for any published studies through June
2020 with the search strategy: ([laser* OR photodynamic*]) AND
(Isotretinoin OR Accutane OR Roaccutane OR Amnesteem OR Claravis
OR Absorica OR Isotroin OR Epuris)[all]. No language restriction was
applied, and inclusion/exclusion criteria were assessed (supplemental
Table S1). We checked the bibliographies further potentially eligible
studies. We used the Oxford Center for Evidence-Based Medicine
Levels of Evidence5 to assign the appropriate value to facilitate data
synthesis.
2.2 | Quality assessment
The Cochrane Methods Bias Group's Risk of Bias in Non-Randomized
Studies - of Interventions (ROBINS-I) Tool6 was used to assess risk of
bias in studies by two review authors, with disagreements resolved by
a third author (supplemental Table S2).
2.3 | Data synthesis
Two researchers extracted data. The outcomes related to the review
question considered the efficacy (eg, cosmetic improvement) or
adverse events (eg, scarring, keloids) associated with concomitant use,
and if a control group was provided, the comparison of these out-
comes between groups.
3 | RESULTS
After an iterative process of cross referencing, 29 studies met the
inclusion criteria (supplemental Figure 1).
The 29 retrieved studies include one expert opinion, eight case
reports, 11 uncontrolled open-label trials, and eight controlled open-
label trial, and included an aggregate of 871 patients (Table 1).
3.1 | Controlled open-label trials
One study considered the difference between patients undergoing
isotretinoin and laser treatment with patients on prescription alone.
Moradi et al14 enrolled 148 patients for laser resurfacing on oral iso-
tretinoin for acne scarring. The intervention arm was treated with
three Nlite and five weekly Er: YAG sessions whereas the age-matched
control group received isotretinoin alone. At 6 months post-treatment,
rates of post-inflammatory hyperpigmentation were the same between
groups at 3%.
Two studies used a split-face model. Saluja et al28 and Xia et al30
conducted a randomized split-face control trail on 10 and 18 patients,
respectively, for acne or acne with treatments with an erbium-doped
laser. Patients showed improvement in scarring without adverse
effects, and for the latter, significantly improved comedo lesions on
the non-ablative fractional laser (NAFL)-treated half-faces.
Five studies subjected all patients to laser treatment and com-
pared a group with concomitant isotretinoin use with a control group
not on isotretinoin. Leal and Cantu17 treated 60 patients for acne scar-
ring with fractionated erbium laser on and off low-dose of isotretinoin;
no difference or variation on the erythema, edema, and scabbing in the
recovery process was observed. Kim et al25 evaluated 20 patients on
fractional ablative carbon dioxide laser treatment with moderate to
much improved cosmetic scores, and erythema and crust associated
with laser treatment in both groups resolved in all patients within
1 month. Chandrashekar et al24 compared 60 patients treated with
either carbon dioxide or 980 nm diode on isotretinoin (0.5 mg/kg);
roughly 8% of those treated with carbon dioxide laser experienced
hyperpigmentation that resolved within 2 months, and all report excel-
lent results. Yoon et al23 enrolled 35 participants who underwent acne
scar revision with a 1550 nm erbium-doped laser, where 94% of the
concomitant group showed improvement vs 88% of the control. No
adverse events were reported. Kim et al34 demonstrated the safe use
of CO2 laser therapy and fractional microneedle radiofrequency for
acne and acne scarring in 43 patients compared to 28 patients not on
isotretinoin. Those on concomitant treatment had improved scar global
assessment scores, and no persistent side effects were observed.
3.2 | Uncontrolled open-label trials
Five studies focused on laser hair removal, four on acne scar revision,
and three on a combination or other.
Khatri9 reported 810 nm diode laser hair removal on the axilla, bikini,
and chin in seven female patients, and 1-month post-treatment, no scar-
ring was found. One patient developed a transient bulla that resolved
spontaneously within 1 month. Cassano et al10 presented six women
undergoing laser hair removal on the face, where one patient presented
with a sparse dotted crusting that healed spontaneously within a few
days. Khatri and Garcia12 described six female patients with satisfactory
hair removal and no scarring during the 6 month follow-up. Khatri13
reviewed 11 patients who underwent laser hair with a 1064 nm Nd:YAG
laser where one patient experienced transient hyperpigmentation that
resolved within 3 months. This rate of complications was not higher than
that observed with patients taking isotretinoin alone.
Hann et al15 used a 1550 nm infrared fractional laser to treat acne
scarring in 35 patients. Using a five-point cosmetic scale, over 80%
of patients demonstrated moderate to excellent improvement, and
no hypertrophic scarring or keloids were found. Jeong et al20 treated
20 patients on isotretinoin with a single session of full-face ablative
fractional carbon dioxide laser. At four-year follow-up, and acne scar
revision was deemed satisfactory. Khatri et al26 tested three sites on a
19-year-old man's lower back with a nonablative fractional laser, an
ablative fractional laser, and a full ablative laser on 40 mg twice daily
isotretinoin for 4 months. Clinical assessment and a 4-mm punch
biopsy was performed at each treatment site during the six-month
follow-up visit. While the sites treated with fractional laser showed
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normal appearing skin, the full ablative laser treatment site showed
a mildly erythematous scar. However, researchers note the settings
for this treatment site were “aggressive.” Moradi et al11 treated
112 patients on isotretinoin for facial nevi, hair removal, acne scarring,
and keloids with one of seven lasers. During a six-month follow-up, no
significant changes on wound healing, long-standing erythema, scars,
and keloid formation were observed. Gold et al32 administered low-
dose isotretinoin in combination with Nd:YAG laser treatments and
found significant reduction in acne scarring without any complications.
Alissa et al in 201116 enrolled 100 patients on isotretinoin ther-
apy for treatment with erbium, vascular, Q-switched alexandrite,
532 nm Q-switched, 1064 nm Nd:YAG, and non-ablative fractional
laser. No hypertrophic scars or keloid development was noted.
Mahadevappa et al in 201627 treated 163 patients with fractional or
full face CO2, fractional Er:YAG, Q switched Nd YAG, long pulse Nd-
YAG, or long pulsed diode lasers on concomitant isotretinoin for hair
removal or acne scarring. Three patients exhibited transient erythema
or pigmentation that resolved. Kwon et al33 demonstrated statistically
significant improvement from baseline of recalcitrant papulopustular
rosacea with pulse dye laser, fractional microneedling, and concomi-
tant isotretinoin without any adverse events.
3.3 | Case reports
Zachariae7 observed one woman with rosacea undergo two argon
laser sessions with minor transient erosions. One month after starting
60 mg daily isotretinoin, she was treated in the same area and found
that the lesions took more than 8 weeks to heal, and 4 weeks later
she developed keloid scarring at these sites. A keloid on her left
knee was found, indicating a tendency to form keloids. Bernestein and
Geronemus8 reported a case of an Asian woman treated for a capillary
vascular malformation of her neck with a 585 nm pulsed dye laser.
After five treatments without adverse effects, she began isotretinoin
and developed keloid scarring 2 weeks after her next treatment.
Han et al19 described a case of cutaneous Rosai-Dorfman Disease
managed with 10 mg twice daily isotretinoin and pulsed dye laser
treatment with no adverse events. Park et al21 treated a 57-year-old
woman with multiple eccrine hidrocystoma with 20 mg daily isotreti-
noin followed by a single CO2 laser session. Good effect was
achieved, though eventually the lesion recurred. Similarly, Noh et al22
used two sessions of CO2 laser and isotretinoin 150 mg/kg to clear
previously laser-resistant sebaceous hyperplasia of the face, which
responded well clinically without side effects or recurrence.
Pestoni et al29 used concomitant tretinoin and fractional CO2
laser on two patients for successful treatment of nodulocystic acne,
resulting in improvement without significant adverse events. In addi-
tion, Demirkan et al31 used a single session of Er:YAG laser and iso-
tretinoin to successfully treat multiple eccrine hidrocystoma without
recurrence at 1 year. No adverse events were reported.
Ma et al35 successfully use six sessions of 595 nm pulse-dye laser
treatment with isotretinoin to treat lupus miliaris disseminates faciei
without side effects.T
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3.4 | Expert opinion
Patwardhan et al18 reported that their practice has been treating
patients on isotretinoin concomitantly with the alexandrite laser for
hair reduction for over a decade. Due to early case reports, lower flu-
encies were used on patients, but have since been modified to the
same laser settings for both patients with and without a prescription
for isotretinoin. The degree of erythema and perifollicular edema were
comparable to those not on isotretinoin therapy. Patients are also
treated with a Nd: YAG and microfractional erbium glass laser for acne
scarring while on isotretinoin and the results have been comparable
or superior to those patients not on oral isotretinoin.
4 | DISCUSSION
4.1 | Summary
Studies considering concomitant laser and isotretinoin use consisted
of 871 patients, the highest collated to date on this topic. Of these,
587 sought acne scar revision and 84 sought laser hair removal. Four-
teen experienced adverse effects7-10,13-15,24,26; 12 of these were tran-
sient hyperpigmentation or eruptions resolving spontaneously. Three
papers suggested that this was equal to the rate of complications in
the control group (use of isotretinoin alone).14,24,25 Two demonstrated
keloid scarring. Both of these patients were cited in case reports that
fall among the lowest level of evidence of all studies and among these
two, one patient was deemed “keloid-prone.” This systematic review
represents the largest cohort of patients assessed for adverse events
to concomitant isotretinoin and laser therapy to date.
4.2 | Quality assessment
Recommendations on this important topic is limited by the lack of
high-quality evidence of randomized controlled trials. Therefore, this
systematic review does not include level 1 evidence. However, there
are 5 level 2, 10 level 3, 3 level 4, and only one level 5 report. The
majority of studies included are level 3 or higher. This review con-
siders a greater body of evidence than that used to formulate current
guidelines.
It is important to consider the limitation of all studies included
in this review, including pre-intervention (eg, confounding, selection),
peri-intervention (eg, classification), and post-intervention (eg, reporting)
bias. Eight studies7,8,18,19,21,22,29,31 were critically biased due to the
inherent limitations of case reports and expert opinions of selective
reporting and negative self-controls. The remainder were moderately
biased, due to no pre-registered protocols, variable isotretinoin
dosages and laser settings, and the subjective nature of outcome
measures. Critically biased studies were the only to report keloid for-
mation, whereas moderately biased studies reported transient adverse
events, if any.
At a study level, limitations may include incomplete retrieval of
all studies related to this topic or reporting bias. The inclusion of
12 databases and no language restrictions help counteract these
forms of bias.
4.3 | Adverse events of isotretinoin alone
In considering any treatment regimen that includes more than one
element, adverse events may be associated with both interventions
together or due to one alone, crucial in the case of adverse events of
concomitant isotretinoin and lasers. Spontaneous keloid transforma-
tion following isotretinoin therapy has been described in several case
reports in which the patient has not been exposed to laser treatment,
suggesting that these complications may be inherent to the medica-
tion rather than lasers.36,37 Therefore, it is possible that the presenta-
tion of keloids in two patients included in this systematic review may
be due to isotretinoin alone.
4.4 | Recommendation
The summary of recommendations by treatment is described in
Table 2. The majority of studies determine that laser intervention—
whether for acne scar revision, hair removal, or otherwise—is associ-
ated with small or absent risk and produces a grade 1 recommendation
due to consistent findings. Contraindication produces a grade 2B
recommendation low-quality evidence of two case reports of one
patient each.
Adverse events associated with different lasers and dosages of
isotretinoin are described in Table 3. Ablative, nonablative, or a com-
bination of laser therapies may be used during systemic isotretinoin
treatment. There are no reliable differences between ablative and
non-ablative laser therapy as keloid formation occurred in patients
TABLE 2 Summary of recommendations by laser intervention
Recommendation Grade of Recommendation38 Level of Evidence5
Safe Acne or acne scar revision11,14,15,17,18,20,23-30,32,34
Laser hair removal9-13,18,24,27
Other (1116192122313335)
1
1
1
2, 3, and 5
2, 3, and 5
3, 4, and 5
Contraindicated Acne scar revision
Laser hair removal
Other(78)
2B 4
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TABLE 3 Adverse events sorted by laser subtype and isotretinoin dose
Ablative/
nonablative Laser Type Laser Dosage Adverse Events References
Ablative Argon Argon, 1.3 W,0.2 second 60 mg QD Keloid formation in keloid-prone
patient
7
CO2 10 600 nm CO2 fractional
38-42 mJ,5.51 J/cm2
0.0005 Transient hyperpigmentation, self-
resolving
29
1550 nm infrared fractional 10 mg QD Transient mild acneiform eruption 15
CO2, 30 W, 1 ms 10–40 mg/d QD Erythema/ crust, resolved 1 month. 25
Ultrapulse CO2, 800 W, 20-Hz,
0.3-msec
20 mg 6w 21
CO2 150 mg/kg 22
Ablative fractional CO2 Variable 20
Ablative fractional Varies 34
Erbium 1550 nm erbium-doped, 35–40 mJ,
8 passes
10 mg QD 23
Er:YAG (19 J, 2 mm spot size, 3 Hz) 20 mg QD 31
Fractionated erbium (50–70 mJ) 20 mg QD 17
Erbium doped 1550 nm NAFL 125–325 mg/kg 28
Nonablative Diode 810 nm diode 0.3–0.5 mg/kg QD Spontaneously healing sparse
crusting
10
810 nm diode, 80/90 W, 300 ms 20–80 mg QD Transient bulla, resolved in 1 month 9
Erbium: glass
fractional
1550 nm Erbium: glass fractional
(20 mJ/cm2, 100–169 points per
area)
10 mg QD Mild transient erythema 30
Multiple Long-pulsed Nd-YAG laser and
microfractional erbium glass
Variable 18
Nd:YAG Nd:YAG 0.2–0.3 mg/kg/d 32
1064 nm Nd: YAG, 30–50 J/cm2,
10-30 ms
0.5 mg/kg QD Transient hyperpigmentation,
resolved in 3 months
13
Pulsed Dye Pulsed dye 10 mg BID 19
595 nm Pulsed-dye (5–8 J/cm2) 10 mg QD 33
595 nm pulsed dye 7.5–8.5 J/cm2,
1.5 ms
10 mg QD 35
585 nm pulse dye,6.0 J/cm2 Unknown Keloid formation 8
Pulser 1200 nm pulser, 22-27 J/cm2,20 ms 40–80 mg QD None 12
Multiple Multiple (a) CO2; (b) diode 980 nm hair
removal
0.5 mg/kg QD +
topical medication
(a) 8% patients transient
hyperpigmentation, resolved
1–2 months; (b) none
24
(a) Nlite, 3 J/cm2; (b) ER: YAG,
0.6–0.7 J/cm2
1 mg/kg QD Hyperpigmentation at equal rate
(3%) in both groups.
14
(a) Long-pulsed Nd:YAG
(1064 nm,9 mm,30 ms,40 J/cm2)
(b) Fractional ER:YAG 2940 nm,
long pulse or scanner (c) Fractional
CO2 30 mj,pulse 0.04 second,100
pixel (d) Full face conventional
CO2 resurfacing 3 mm
spot,500 Hz (e) Q-switched Nd:
YAG 1.5 mm spot,400mj
2–110 mg/kg (a) None (b) resolving post-
inflammatory pigmentation (c-d)
None (e) transient erythema
27
(a) Nonablative fractional (1540 nm,
100 mJ/mB, 3 passes); (b) ablative
fractional laser (erbium:YAG
2940 nm, 91 J/cm2, 3 passes); (c)
full ablative (erbium:YAG
2940 nm, 2 J, 8 passes)
40 mg BID (a) None; (b) None; (c) Mild
erythematous scar
26
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under both modalities, and notably, these were case reports from
prior to the turn of the century in possibly patients that were keloid-
prone at baseline. In addition, isotretinoin dosage does not appear to
impact the occurrence of adverse events as a patient on 60 mg qd
developed a keloid, while no adverse events were noted in patients
on even higher doses. Due to the two brief reports of adverse events
occurring in patients prone to keloid formation, physicians should
evaluate whether the patient is susceptible to pigmentation, scars, or
keloid formation and consider a test treatment area prior to treat-
ment as a standard.7,8 Patients should also be recommended to use a
mild cleanser and moisturizer as well as sunscreen and sun avoidance
post-treatment to decrease any possible associated risks.39,40
The results of this systematic review are promising for patients
and providers wishing to continue isotretinoin during laser treatment.
We conclude that though there may be a risk associated with con-
comitant use of isotretinoin and lasers, the body of evidence indicates
that this risk is relatively small or absent. Recent studies have demon-
strated no difference in wound healing perioperatively between those
individuals on systematic isotretinoin vs control.41 Further robust
studies should be conducted to provide additional evidence that may
challenge the current guidelines contraindication.
5 | CONCLUSION
The data presented fails to show long-term adverse effects of con-
comitant use of isotretinoin and lasers. It does not prove that isotreti-
noin use is safe at all dosages and with all lasers at all parameters.
Further high-quality randomized controlled trials with a larger number
of patients and treatments must be performed before it is concluded
that concomitant use is completely safe in patients.
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